The Motley Fool
27 Jun 2026, 10:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Vertex Pharmaceuticals generated nearly $12 billion in FY 2025 revenue, an 8.9% year-over-year increase, with a net income of approximately $4.0 billion. — Strong revenue growth and high profitability in a dominant market position signal stability and lower risk for investors.
+0.60CRISPR Therapeutics saw FY 2025 revenue decline by approximately 90.0% to nearly $3.5 million, reporting a net loss of $581.6 million. — A massive revenue drop and significant net losses highlight the high-risk, pre-profit nature of the company's current stage.
-0.50CRISPR Therapeutics relies on Vertex Pharmaceuticals for commercial infrastructure, sharing CASGEVY profits and losses on a 40/60 split. — High customer and partner concentration creates a structural dependency that increases operational risk for CRISPR Therapeutics.
-0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Both companies maintain low debt-to-equity ratios, with CRISPR at 0.2x and Vertex at 0.4x as of December 2025. — Low leverage across both firms reduces bankruptcy risk and provides flexibility for future R&D investment.
+0.20Which stocks this story touches
The company shows strong financial health with $12 billion in revenue, high profitability, and a dominant position in the cystic fibrosis market.
The company reports a massive revenue decline and significant net losses, though it maintains a strong balance sheet and high-growth potential.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
14h ago
